Paradigm updated their coverage to a buy.
You can email Paradigm for a copy.
Author : Scott McAuley, PhD, Analyst
expanded use numbers and new target price.
Going from 120,000 annual addressable patients with penetration of 35% (42,000 patients) to now using 280,000 patients at 20% penetration (56,000 patients)
You can email Paradigm for a copy.
Author : Scott McAuley, PhD, Analyst
expanded use numbers and new target price.
Going from 120,000 annual addressable patients with penetration of 35% (42,000 patients) to now using 280,000 patients at 20% penetration (56,000 patients)
Getting the standard of care from the FDA would be huge..this type of gut sepsis with high endotoxin stands as untreatable barring standard antibiotics witch have a poor success rate....
Hang tight...
NCI Dictionary of Cancer Terms
NCI's Dictionary of Cancer Terms provides easy-to-understand definitions for words and phrases related to cancer and medicine.
www.cancer.gov
Been a little weary of posting anything directly from analysis reports..some are just for paying clients...
This is copied off another board in reference to the Paradigm report mentioned above.
"In fairness, Paradigm is trying to walk a fine line of having Spectral as a client, while also being in charge of finding investors to purchase our paper. I definitely think they were way too conservative with their estimates, but I also undertand their desire to appear somewhat unbiased just prior to a raise. They do acknowledge how conservative they were being, and they offer this paragraph as a sort of mea culpa."
New Analysis Highlights Upside to Market Assumptions
The company also presented Incidence of Endotoxic Septic Shock in the U.S. and Canada. Additional
analysis of the prior EUPHRATES Phase 3 trial led to an updated estimate that ~37.3% of all septic
shock patients in Canada and the U.S. have endotoxic septic shock (ESS), which is defined by endotoxin activity assay (EAA) level >0.6. Based on different estimates of septic shock incidence in the U.S., anywhere from 180,000380,000 patients per year have this ESS subset of septic shock. We have been using a total endotoxemic septic shock market opportunity of 120,000 per year in our assumptions. Therefore, these new estimates provide 50217% upside to our market estimates.
This is copied off another board in reference to the Paradigm report mentioned above.
"In fairness, Paradigm is trying to walk a fine line of having Spectral as a client, while also being in charge of finding investors to purchase our paper. I definitely think they were way too conservative with their estimates, but I also undertand their desire to appear somewhat unbiased just prior to a raise. They do acknowledge how conservative they were being, and they offer this paragraph as a sort of mea culpa."
New Analysis Highlights Upside to Market Assumptions
The company also presented Incidence of Endotoxic Septic Shock in the U.S. and Canada. Additional
analysis of the prior EUPHRATES Phase 3 trial led to an updated estimate that ~37.3% of all septic
shock patients in Canada and the U.S. have endotoxic septic shock (ESS), which is defined by endotoxin activity assay (EAA) level >0.6. Based on different estimates of septic shock incidence in the U.S., anywhere from 180,000380,000 patients per year have this ESS subset of septic shock. We have been using a total endotoxemic septic shock market opportunity of 120,000 per year in our assumptions. Therefore, these new estimates provide 50217% upside to our market estimates.
just looked at the report..as I said the above was copied from another site.
Not positive how he came up with the %
Verbatim from the report: below.
"Updating Market Assumptions | Recent analysis by EDT indicates that the market
opportunity is likely larger than our initial estimate. We have been using 120,000
patients as the annual addressable market opportunity, with peak sales penetration
at 35% (42,000 patients). Updated analysis of the Phase 3 EUPHRATES data
presented at the Society of Critical Care Medicine’s Annual Congress suggests that
the market for endotoxemic septic shock could be between 180,000 and 380,000
patients per year. We have updated our peak estimates to be 20% of 280,000,
resulting in 56,000 patients per year."
